Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study

SIMPLE SUMMARY: Ipilimumab and Nivolumab (IPI-NIVO) improved survival in a pivotal phase III trial conducted in patients with metastatic Renal Cell Carcinoma (mRCC) with intermediate or poor International Metastatic RCC Database Consortium (IMDC) score when compared to sunitinib. A compassionate use...

Descripción completa

Detalles Bibliográficos
Autores principales: Basso, Umberto, Paolieri, Federico, Rizzo, Mimma, De Giorgi, Ugo, Bracarda, Sergio, Antonuzzo, Lorenzo, Atzori, Francesco, Cartenì, Giacomo, Procopio, Giuseppe, Fratino, Lucia, D’Arcangelo, Manolo, Fornarini, Giuseppe, Zucali, Paolo, Cusmai, Antonio, Santoni, Matteo, Pipitone, Stefania, Carella, Claudia, Panni, Stefano, Deppieri, Filippo Maria, Zagonel, Vittorina, Tortora, Giampaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105283/
https://www.ncbi.nlm.nih.gov/pubmed/35565422
http://dx.doi.org/10.3390/cancers14092293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105283/
https://www.ncbi.nlm.nih.gov/pubmed/35565422
http://dx.doi.org/10.3390/cancers14092293

Ejemplares similares